Eric Dane

Company: AstraZeneca

Job title: Associate Principal Scientist

Bio:

At AstraZeneca Boston, Eric is the lead chemist for the Advanced Drug Delivery group’s work on novel excipients for lipid nanoparticles (LNPs). The group’s efforts are focused on improving the safety, stability, and formulatability of LNPs while enabling their use in emerging therapies requiring systemic targeting of extrahepatic cells and tissues. Eric received his PhD in organic materials chemistry from MIT in 2010 and then developed new biomaterials for drug delivery as an NIH postdoctoral fellow at Boston University. Subsequently, as a Research Scientist in Darrell Irvine’s lab at MIT he developed PEGylated lipid nanodiscs for the delivery of STING agonists to tumors for cancer immunotherapy before transitioning to industry to focus on non-viral mRNA delivery.

Seminars:

Overcoming Immunogenicity Challenges in Extrahepatic mRNA-LNP Delivery 3:00 pm

Discuss why efforts to go beyond the liver can heighten immune risk and how to design smarter LNPs that minimize it Review approaches to control innate immune responses when directing LNPs to organs like the heart, lung, or spleen Discover how administration methods and LNP composition influence immune profiles in non-hepatic targetingRead more

day: Conference Agenda

Q&A Session 3:50 pm

Join our speakers for an interactive Q&A session, where they’ll come together to answer your questions, share further insights, and expand on key themes from their presentations.Read more

day: Conference Agenda